[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR066667A1 - PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT - Google Patents

PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT

Info

Publication number
AR066667A1
AR066667A1 ARP080102158A ARP080102158A AR066667A1 AR 066667 A1 AR066667 A1 AR 066667A1 AR P080102158 A ARP080102158 A AR P080102158A AR P080102158 A ARP080102158 A AR P080102158A AR 066667 A1 AR066667 A1 AR 066667A1
Authority
AR
Argentina
Prior art keywords
agent
pharmaceutical compositions
lipstatine
combination
hmg coa
Prior art date
Application number
ARP080102158A
Other languages
Spanish (es)
Inventor
Ochoa Victor Guillermo Alvarez
Armenta Maria Elena Garcia
Murillo Josefina Santos
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of AR066667A1 publication Critical patent/AR066667A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Composiciones farmacéuticas caracterizadas por estar compuestas por la combinacion sinérgica de un agente derivado hidrogenado de lipstatina, tal como lo es el principio activo: Orlistat y un agente inhibidor de la enzima HMG-CoAreductasa, tal como lo son los principios activos: Simvastatina y/o Rosuvastatina, además de excipientes farmacéuticamente aceptables; en donde los rangos de concentracion que se encuentran presentes en la formulacion para el Orlistat son de 60.0mg. a 120.0 mg., para la Simvastatina son de 20.0 mg. a 40.0 mg. y para la Rosuvastatina son de 5.0 a 10.0 mg; mismos que se encuentran formulados en una sola unidad de dosificacion para ser administradas por vía oral, las cuales están indicadaspara la prevencion y/o tratamiento de la hipercolesterolemia, trigliceridemia, el sobrepeso y la obesidad.Claim 1: Pharmaceutical compositions characterized by being composed of the synergistic combination of a hydrogenated derivative agent of lipstatin, such as the active ingredient: Orlistat and an inhibitor of the enzyme HMG-CoAreductase, such as the active ingredients: Simvastatin and / or Rosuvastatin, in addition to pharmaceutically acceptable excipients; where the concentration ranges that are present in the formulation for Orlistat are 60.0mg. at 120.0 mg., for Simvastatin they are 20.0 mg. at 40.0 mg and for Rosuvastatin they are 5.0 to 10.0 mg; same that are formulated in a single dosage unit to be administered orally, which are indicated for the prevention and / or treatment of hypercholesterolemia, triglyceridemia, overweight and obesity.

ARP080102158A 2007-05-21 2008-05-21 PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT AR066667A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007006092A MX2007006092A (en) 2007-05-21 2007-05-21 Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent.
PCT/MX2008/000062 WO2008143491A1 (en) 2007-05-21 2008-05-19 Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent

Publications (1)

Publication Number Publication Date
AR066667A1 true AR066667A1 (en) 2009-09-02

Family

ID=40032121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102158A AR066667A1 (en) 2007-05-21 2008-05-21 PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT

Country Status (4)

Country Link
AR (1) AR066667A1 (en)
MX (1) MX2007006092A (en)
UY (1) UY31096A1 (en)
WO (1) WO2008143491A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314232A (en) * 2019-08-03 2019-10-11 黄泳华 The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor
CN110357812A (en) * 2019-08-03 2019-10-22 黄泳华 The eutectic compound being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319170B2 (en) * 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives

Also Published As

Publication number Publication date
WO2008143491A1 (en) 2008-11-27
MX2007006092A (en) 2009-02-25
UY31096A1 (en) 2008-11-28

Similar Documents

Publication Publication Date Title
NO20080284L (en) Cannabionoid active pharmaceutical ingredient for improved dosage forms
BRPI0508540A (en) compound, pharmaceutical composition, and use of a compound
CO6251259A2 (en) PHARMACEUTICAL FORMULATIONS OF ESTRIOL IN LOW DOSE
RS52922B (en) Compositions and uses for treating multiple sclerosis
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
MX2009003372A (en) Non-mucoadhesive film dosage forms.
ATE493973T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
WO2009026473A3 (en) Stabilized therapeutic compositions and formulations
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
AR068820A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF VENOTONIC AGENTS AND VASOPROTECTORS FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY AND USE
CL2010000524A1 (en) Use of a topical composition comprising 3.75% imiquimod and a pharmaceutically acceptable carrier to prepare a medicament useful for treating genital or perianal warts.
CL2009001267A1 (en) Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.
UY30847A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
AR066666A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT
BRPI0409878A (en) compounds, pharmaceutical compositions, method for the treatment or prophylaxis of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds
AR066667A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT
ATE460934T1 (en) PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN
CL2024001520A1 (en) New oral pharmaceutical composition and dosing regimen for the therapy of interstitial lung diseases
RU2013105513A (en) Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases
CO6270220A2 (en) PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES
RU2011113733A (en) Derivatives of 1-amino-alkylcyclohexane for the treatment of cognitive impairment in noise in the ears
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
AR067320A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTIONS
AR037543A1 (en) METHOD FOR CANCER THERAPY AND PHARMACEUTICAL COMPOSITION
AR067700A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINE ENZYME INDICATED FOR THE CONTOL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA

Legal Events

Date Code Title Description
FB Suspension of granting procedure